Latest Breaking News On - Jennifer minai azary - Page 1 : comparemela.com

Context Therapeutics Reports First Quarter 2024 Operating and Financial Results

Context Therapeutics Announces FDA Clearance of IND Application for a Phase 1 Clinical Trial of ...

CTIM-76Phase 1 clinical trial to focus on CLDN6-positive gynecologic and testicular cancers

Context Therapeutics Announces FDA Clearance of IND Application for a Phase 1 Clinical Trial of CTIM-76

CTIM-76 Phase 1 clinical trial to focus on CLDN6-positive gynecologic and testicular cancers Company expects to enroll first patient in mid-2024 PHILADELPHIA, May 02, 2024 Context Therapeutics.

Context Therapeutics Announces $100 Million Private Placement

Financing includes new and existing leading healthcare investors

Context Therapeutics Submits IND Application to Evaluate CTIM-76 in Claudin 6-Positive Cancers

Important Regulatory Milestone Supports Next Phase of CTIM-76 DevelopmentPHILADELPHIA, April 01, 2024 Context Therapeutics Inc. , a biopharmaceutical company advancing medicines for solid.